1. GPCR/G Protein
  2. Prostaglandin Receptor

Iloprost (Synonyms: ZK-36374; Ciloprost; ZK36374; ZK 36374)

Cat. No.: HY-A0096 Purity: 99.83%
Data Sheet SDS Handling Instructions

Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2.

For research use only. We do not sell to patients.
Iloprost Chemical Structure

Iloprost Chemical Structure

CAS No. : 78919-13-8

Size Price Stock Quantity
10 mM * 1 mL in DMSO $278 In-stock
1 mg $90 In-stock
2 mg $150 In-stock
5 mg $350 In-stock
10 mg $550 In-stock
25 mg $950 In-stock
50 mg $1600 In-stock
100 mg $2600 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2. Target: Iloprost is a stable prostacyclin analog commonly employed in the treatment of peripheral vascular disease and also indicated in the treatment of patients affected by systemic sclerosis (SSc) in the presence of severe Raynaud's phenomenon (RP). [1] Iloprost dilates systemic and pulmonary arterial vascularbeds. Iloprost also affects platelet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer.[2] Iloprost is a stable carbacyclin derivative of prostacyclin, was studied during electrically-induced coronary artery thrombosis in the open chest anesthetized pig. Infusion of ZK 36374 (100 ng/kg/min, n = 6) had no effect on heart rate and cardiac output, but caused a 20% reduction in mean arterial blood pressure by peripheral vasodilation. In animals receiving solvent or no drug prior to thrombosis induction, the time to occlusive coronary artery thrombosis (TOT) was 30 +/- 2 minutes (mean +/- SEM, n = 17). Pretreatment with an i.v. infusion of ZK 36374 (100 ng/kg/min) prolonged TOT by 50% to 47 +/- 7 minutes (p less than 0.005, n = 6). This prolongation of TOT was not due to the lower blood pressure in the ZK 36374 group, as dihydralazine in a dose that lowered arterial blood pressure to the same extent had no effect on TOT (32 +/- 4 minutes, n = 4). The results indicate that ZK 36374 may be useful in delaying (or preventing) occlusive coronary artery thrombi. [3]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00561223 University of Oklahoma Chronic Obstructive Pulmonary Disease|Pulmonary Hypertension September 2006
NCT00467896 Actelion Pulmonary Hypertension September 2006 Phase 2
NCT00723554 Actelion Pulmonary Arterial Hypertension July 2008 Phase 3
NCT00709098 Actelion Pulmonary Arterial Hypertension September 2008 Phase 3
NCT01274481 University of Oklahoma|Actelion Acute Respiratory Distress Syndrome|Acute Lung Injury|Pulmonary Hypertension March 2011 Phase 1
NCT00981591 Seattle Children's Hospital|Actelion Pulmonary Hypertension|Neonatal Hypoxic Respiratory Failure|Persistent Pulmonary Hypertension of Newborn|Congenital Heart Defects|Acute Respiratory Distress Syndrome September 2009 Phase 1|Phase 2
NCT01319045 University of California, Los Angeles|Actelion Pulmonary Arterial Hypertension|Congenital Heart Disease|Eisenmenger's Syndrome June 2011
NCT00724321 Loma Linda University Hypoxic Pulmonary Vasoconstriction July 2008 Phase 1
NCT00708565 VA Loma Linda Health Care System|Actelion Hypoxic Pulmonary Vasoconstriction July 2008 Phase 1
NCT02826252 Bayer Hypertension, Pulmonary September 15, 2016
NCT01209533 Vanderbilt University|Actelion Asthma September 2010 Early Phase 1
NCT00409526 University of Chicago Pulmonary Hypertension December 2006 Phase 4
NCT00902603 Actelion Pulmonary Arterial Hypertension March 2009
NCT00709956 Actelion Pulmonary Arterial Hypertension July 2008 Phase 3
NCT00403650 University of Cincinnati Sarcoidosis|Pulmonary Arterial Hypertension November 2006 Phase 4
NCT00927654 Ludwig-Maximilians - University of Munich|Algora Pulmonary Hypertension June 2009 Phase 3
NCT01598441 Shanghai Jiao Tong University School of Medicine|Cardiothoracic Surgical Group of Chinese Society of Pediatric Surgery Pulmonary Hypertension June 2012 Phase 3
NCT01320878 Shanghai Jiao Tong University School of Medicine Pulmonary Hypertension October 2007 Phase 2
NCT01437878 Actelion Chronic Obstructive Pulmonary Disease|Pulmonary Hypertension March 2012 Phase 2
NCT01941225 Louisiana State University Health Sciences Center in New Orleans Chronic Obstructive Pulmonary Disease September 2013 Phase 2
NCT01458041 Bayer Peripheral Arterial Disease August 2011
NCT03111212 University Hospital Tuebingen Respiratory Distress Syndrome, Adult June 2018 Phase 3
NCT02482402 Heidelberg University|Bayer Chronic Left Ventricular Failure|Pulmonary Hypertension February 2015 Phase 2
NCT01116063 Carmel Medical Center Chronic Obstructive Pulmonary Disease May 2010 Phase 4
NCT01894035 Bayer Pulmonary Hypertension September 23, 2013
NCT00235521 Heidelberg University Pulmonary Hypertension May 2005
NCT00345501 Onassis Cardiac Surgery Centre Renal Insufficiency, Chronic|Coronary Angiography|Angioplasty, Transluminal, Percutaneous Coronary November 2005 Phase 2|Phase 3
NCT01549171 Fertility Specialists of Houston|Origio A/S Pregnancy January 2010
NCT01781052 Bayer Pulmonary Arterial Hypertension September 2013
NCT00622687 Charite University, Berlin, Germany|Schering-Plough Systemic Sclerosis September 1997 Phase 2
NCT02825160 Bayer Hypertension, Pulmonary August 1, 2016
NCT00185315 Bayer Hypertension, Pulmonary February 2000 Phase 3
NCT00084409 University of Colorado, Denver|National Cancer Institute (NCI) Lung Cancer|Precancerous Condition November 2001 Phase 2
NCT00439543 Interstitial Lung Disease Study Group, Korea Pulmonary Fibrosis|Pulmonary Hypertension March 2007 Phase 2|Phase 3
NCT01355380 Bayer Pulmonary Arterial Hypertension August 2010 Phase 4
NCT02237183 National Cancer Institute (NCI) Lung Carcinoma|Mild Dysplasia|Precancerous Condition November 5, 2015 Phase 1
NCT01310751 Shanghai Jiao Tong University School of Medicine Pulmonary Hypertension January 2011 Phase 2|Phase 3
NCT00414687 Bayer Hypertension, Pulmonary July 1998 Phase 2
NCT00086463 Actelion Pulmonary Arterial Hypertension|Ayerza Syndrome|Pulmonary Hypertension June 2004 Phase 2
NCT00216931 Lund University Hospital|Bayer Persistent Pulmonary Hypertension|Respiratory Distress Syndrome May 2006
NCT02784899 Yonsei University Lung Cancer October 2015
NCT01469169 Bayer Hypertension, Pulmonary June 19, 2012 Phase 3
NCT00120380 Hannover Medical School Hypertension September 2004 Phase 4
NCT02204852 Sisse R. Ostrowski, MD PhD DMSc|Rigshospitalet, Denmark Septic Shock September 2014 Phase 2
NCT00109681 Actelion Pulmonary Fibrosis|Pulmonary Hypertension April 2005 Phase 2
NCT00453414 Actelion Pulmonary Arterial Hypertension July 2006 Phase 2
NCT01054105 Gachon University Gil Medical Center|Seoul National University Hospital|Seoul National University Bundang Hospital|The Catholic University of Korea|Bayer Pulmonary Arterial Hypertension October 2010 Phase 4
NCT01712997 Fourth Military Medical University Pulmonary Arterial Hypertension September 2012 Phase 3
NCT02170519 Duke University Pulmonary Hypertension September 2006 Phase 4
NCT01389271 Bayer Pulmonary Hypertension February 3, 2011
NCT01971450 Bayer Hypertension, Pulmonary December 15, 2013
NCT00302211 Actelion Pulmonary Hypertension February 2006 Phase 3
NCT02490657 Yonsei University Video-assisted Thoracoscopic Surgery|Chronic Obstructive Pulmonary Disease July 2015
NCT00250640 Bayer Hypertension, Pulmonary April 2005
NCT00882947 Bayer Primary Hypertension February 2006 Phase 4
NCT01082484 University Hospital, Grenoble Healthy January 2010 Phase 1|Phase 2
NCT01062282 Bayer Pulmonary Hypertension July 2006
NCT00004786 National Center for Research Resources (NCRR)|University of Pittsburgh|Office of Rare Diseases (ORD) Systemic Sclerosis|Raynaud Disease December 1995 Phase 3
NCT01718288 Fadoi Foundation, Italy Peripheral Arterial Disease November 2006 Phase 4
NCT01468545 Bayer|Dra. Pilar Escribano Subías - Coordinator - HU 12 de Octubre - Madrid (Spain) Pulmonary Arterial Hypertension October 2011
NCT02685618 Pär Johansson|Rigshospitalet, Denmark Cardiac Arrest February 2016 Phase 2
View MoreCollapse
References
M.Wt

360.49

Formula

C₂₂H₃₂O₄

CAS No.

78919-13-8

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Iloprost
Cat. No.:
HY-A0096
Quantity: